Basic Salofalk Information

• INN (International Nonproprietary Name): Mesalazine or Mesalamine (also known as 5-aminosalicylic acid, 5‑ASA).
• Brand Names Available In United Kingdom: Asacol (delayed‑release tablets 400 mg and 800 mg), Asacol HD (800 mg delayed‑release in some markets), Pentasa, Mezavant (Lialda in the US), Salofalk, and Rowasa depending on supply and formulation.
• ATC Code: A07EC02 — A07: drugs for inflammatory bowel disease; E: intestinal anti‑inflammatory agents; C: aminosalicylic acid and similar agents; 02: mesalazine/mesalamine.
• Forms & Dosages: Delayed‑release tablet 400 mg (Asacol) in bottles or blisters of 30/60/90; delayed‑release tablet 800 mg (Asacol HD) commonly in packs of 90; rectal enema and suppository formulations available from brands such as Salofalk and Rowasa depending on market supply.
• Manufacturers In United Kingdom: Distributed in the UK market by international suppliers and licensed distributors; manufacturers and suppliers include Tillotts, Zeria, Allergan and Meda Pharma as noted in product registries.
• Registration Status In United Kingdom: Asacol and other mesalazine products are approved for mild‑to‑moderate ulcerative colitis and are prescription‑only in the UK.
• OTC / Rx Classification: Prescription only (Rx) across relevant jurisdictions including the UK.

Key Findings From Recent Trials

What can patients and clinicians expect from the latest studies on mesalazine?

Recent randomised trials and large observational cohorts between 2022 and 2025 reinforced mesalazine's central role for both induction and maintenance in mild–moderate ulcerative colitis.

Several studies demonstrated a clear dose‑response for induction, with higher oral daily doses in the 2.4–4.8 g range producing faster rates of mucosal healing compared with lower doses.

Head‑to‑head comparisons continued to explore release technologies such as delayed‑release (Asacol) versus sustained or extended‑release formulations for adherence and targeted colonic delivery.

Rectal mesalazine remains superior for distal disease, with enemas and suppositories producing reliable local remission for proctitis and proctosigmoiditis.

Safety‑focused cohorts highlighted that renal and hypersensitivity events are infrequent but clinically important, supporting current recommendations for baseline and periodic renal monitoring.

Main Outcomes

• Induction: higher daily dosing improved clinical remission and endoscopic response within typical induction windows.
• Maintenance: daily doses of 1.6–2.4 g were effective at reducing relapse rates during follow‑up.
• Topical Therapy: enemas and suppositories were effective and often preferred for proctitis and proctosigmoiditis.

Safety Observations

Delayed‑release formulations such as Asacol show low systemic absorption, which reduces systemic adverse events compared with older agents.

Despite low absorption, baseline and periodic renal function checks remain recommended due to rare but serious renal adverse reactions.

Clinical Mechanism Of Action

How does mesalazine actually calm inflammation in ulcerative colitis?

Layman’s Explanation

Mesalazine works directly on the lining of the colon to reduce inflammation where ulcerative colitis causes damage.

Delayed‑release tablets, including Asacol, are coated to dissolve in the terminal ileum and colon so the active 5‑ASA acts locally and limits whole‑body exposure.

Scientific Breakdown

At a cellular level, mesalazine modulates local prostaglandin and leukotriene synthesis to blunt inflammatory pathways.

The drug also scavenges free radicals and down‑regulates pro‑inflammatory cytokines such as TNF‑α and IL‑1 in the mucosa.

Topical action within the bowel wall is the primary mechanism of efficacy, and systemic absorption is intentionally limited by formulation design.

Formulation Relevance

• Delayed‑Release (Asacol): pH‑triggered coating releases 5‑ASA in the terminal ileum and colon to target colonic inflammation specifically.
• Rectal Formulations (Salofalk, Rowasa): enemas and suppositories deliver mesalazine directly to distal mucosa for rapid local effect.

The mechanism explains why greater colonic delivery—through higher doses or specific release technologies—improves outcomes while keeping systemic side effects relatively low.

Scope Of Approved & Off‑Label Use

Who is licenced to take Asacol in the UK, and where do clinicians sometimes go beyond the licence?

United Kingdom Approvals

In the UK, Asacol is licensed for induction and maintenance of mild‑to‑moderate ulcerative colitis and is prescription‑only.

Asacol 400 mg is licensed in some formulations for children aged five and older, while the 800 mg formulation is typically adult‑labelled.

NICE and UK clinical practice maintain 5‑ASA agents as first‑line therapy for mild–moderate UC with topical forms recommended for distal disease.

Notable Off‑Label Trends

Off‑label uses reported in practice include adjunctive therapy for pouchitis and investigational or limited use in very mild Crohn’s disease, although efficacy in Crohn’s is not established.

Clinicians may adapt dose or regimen—such as higher induction doses or combined oral plus rectal therapy—depending on disease extent and patient response.

Regulatory summaries and product leaflets should be consulted for country‑specific phrasing and MHRA guidance.

Dosage Strategy

What dosing patterns work best for induction and long‑term control?

General Dosing

Standard adult dosing for induction ranges from 2.4–4.8 g per day given orally in divided doses.

Maintenance dosing commonly uses 1.6–2.4 g per day in divided doses to reduce relapse risk.

Asacol delayed‑release tablets are available as 400 mg (useful in paediatrics) and 800 mg strengths; regimens should reflect each formulation's release characteristics.

Condition‑Specific Dosing

• Mild–Moderate Active UC (Adult): 2.4–4.8 g/day orally in divided doses (for example, 800 mg three times daily to reach 2.4 g, with higher totals up to 4.8 g for more extensive disease).
• Maintenance: 1.6–2.4 g/day in divided doses to prevent relapse.
• Paediatric: Asacol 400 mg may be used from age 5, with typical dosing around 50–75 mg/kg/day divided; 800 mg forms are not routinely approved for under‑18s.

Splitting doses helps keep mucosal exposure steady, and combined oral plus rectal therapy is often effective for left‑sided disease.

Adjust doses for renal impairment and use caution in the elderly with monitoring.

Safety Protocols

What checks should a pharmacist or prescriber perform before and during treatment?

Contraindications

Absolute contraindications include known allergy to mesalazine/mesalamine, aspirin, sulfasalazine or other salicylates, and severe renal impairment or previous severe renal adverse reaction.

Hypersensitivity to any tablet component excludes use, and pregnancy or breastfeeding are relative contraindications—use only if the anticipated benefit justifies the risk.

Adverse Effects

Common, usually mild side effects include headache, nausea, abdominal pain, diarrhoea, flatulence and fatigue.

Moderate or rare reactions can include worsening colitis with bloody diarrhoea, allergic rash or fever, renal dysfunction such as interstitial nephritis, and chest pain or breathlessness.

Severe reactions require immediate cessation and urgent assessment.

Monitoring Recommendations

• Obtain baseline creatinine and perform periodic renal function checks during long‑term therapy.
• Monitor liver enzymes if clinically indicated.
• Reduce dose or avoid use in elderly patients and those with renal disease unless closely monitored.

Interaction Mapping

Will food or other medicines change how mesalazine works?

Food Interactions

There are minimal direct food interactions with mesalazine and colonic delivery is not significantly affected by food.

Patients who experience GI upset can be advised to take tablets with or after food, while following the product leaflet instructions.

Drug Combinations To Avoid

• Salicylates/Sulfasalazine: avoid in patients with known salicylate hypersensitivity.
• Nephrotoxic Agents: concurrent NSAIDs, aminoglycosides, ACE inhibitors or diuretics may increase renal risk; monitor creatinine closely.
• Anticoagulants: mesalazine can potentiate warfarin; INR monitoring is recommended if co‑prescribed.
• Immunomodulators/Biologics: not contraindicated, but specialist oversight is advisable when combining therapies.

Pharmacists should review concurrent medicines and counsel patients on signs of nephrotoxicity or allergic reaction.

Patient Experience Analysis

What do people actually say about taking mesalazine?

Survey Data

Real‑world patient surveys report high satisfaction when mesalazine induces symptomatic improvement, and adherence correlates strongly with dosing frequency and tolerability.

Many patients prefer once‑ or twice‑daily regimens where available, which is one reason extended‑release or modified‑release options are attractive.

Forum Trends

Online patient communities commonly report rapid symptom relief during high‑dose induction and note that rectal forms are often transformative for distal disease.

Challenges raised by patients include multiple daily dosing, large tablet size, and transient GI side effects.

There are frequent concerns about long‑term renal monitoring and switching between brands or generics because release characteristics can differ.

Packaging and paediatric strengths such as Asacol 400 mg, as well as blister versus bottle formats, influence adherence for families.

Shared decision‑making on formulation, dosing frequency and monitoring improves adherence and outcomes in real practice.

Distribution & Pricing Landscape

How easy is it to find mesalazine, and what affects the price?

Mesalazine products such as Asacol, Pentasa, Mezavant/Lialda, Salofalk and Rowasa are supplied by international companies and local generics across the UK market.

Products are prescription‑only and dispensed via community pharmacies or hospital services, with packaging normally available in 30/60/90 tablet packs or branded rectal forms by region.

Generics have pushed down costs for many 5‑ASA products, but release‑technology patents and brand positioning maintain price variability between formulations.

NHS procurement and local formularies often determine preferred brands and may drive switches to generics within trusts.

When switching brands pharmacists should ensure continuity and consider bioequivalence and release‑profile differences which can matter clinically.

Alternative Options

Which mesalazine formulations should clinicians consider if Asacol is unsuitable?

Comparison Table (Narrative)

Major alternatives include Pentasa (sustained‑release mesalazine), Mezavant/Lialda (extended‑release designed for once‑daily dosing in some markets), Salofalk (oral and rectal options) and rectal products such as Rowasa for proctitis.

Pros And Cons

• Asacol (Delayed‑Release): established evidence for induction and maintenance with pH‑triggered colonic targeting; 400 mg option useful for children; con can be multiple daily dosing depending on regimen.
• Pentasa (Sustained‑Release): releases through small bowel and colon which may suit pan‑enteric disease; release differences can change colonic concentration.
• Mezavant/Lialda (Extended‑Release): offers once‑daily dosing in some jurisdictions which aids adherence, but licensing and availability vary by region.
• Rectal Options (Salofalk/Rowasa): rapid, local effect for distal disease but patient acceptability varies.

Clinician decisions should be guided by disease extent, patient preference, renal profile and formulation availability.

Regulatory Status

What do regulators say about Asacol and mesalazine?

Mesalazine is approved by major regulators for ulcerative colitis and related distal indications in many jurisdictions.

The US FDA has approvals for ulcerative colitis, proctitis and proctosigmoiditis and distinguishes formulations such as Asacol HD for adults and Asacol 400 mg for children five years and older.

EU and EEA regulators have accepted Asacol in most markets and Asacol is recognised for mild‑to‑moderate ulcerative colitis in the UK with prescription status.

Product labels across regions mandate renal monitoring and list absolute contraindications including salicylate allergy and severe renal impairment.

NICE guidance in the UK endorses 5‑ASA therapy as first‑line for mild‑to‑moderate disease and local formularies define preferred preparations.

Consolidated FAQ

What are the quick answers patients ask most often?

Common Patient Questions Answered

How quickly does Asacol work? Symptom improvement is often seen within days to weeks, while mucosal healing may take 6–8 weeks during an induction course.

What if I miss a dose? Take the missed dose as soon as you remember unless it is almost time for the next dose; never double up to make up a missed dose.

Is it safe in pregnancy? Use only if benefits outweigh risks and discuss with your obstetrician; neonatal diarrhoea monitoring may be advised if exposure occurs late in pregnancy.

How is Asacol stored? Store between 15–30°C, protect from moisture and sunlight, and keep in the original container away from children.

What should I do about side effects? Stop and seek urgent care for severe rash, chest pain, shortness of breath, or sudden worsening of symptoms and report persistent GI upset to your prescriber.

When To See A Clinician

Seek urgent assessment if you develop worsening bloody diarrhoea, chest pain, reduced urine output or signs of an allergic reaction.

Arrange regular renal checks during long‑term therapy as advised by your prescriber.

Visual Guide

Which images help patients and clinicians understand mesalazine best?

Suggested visuals include a diagram showing the delayed‑release tablet journey with pH thresholds and site of release in the terminal ileum and colon annotated with Asacol.

A flowchart can show induction → reassess at 6–8 weeks → maintenance dosing options (1.6–2.4 g/day) and key monitoring points such as baseline and periodic creatinine.

A comparison infographic can contrast oral versus rectal mesalazine for extensive versus distal disease, with pros and cons and typical doses.

A monitoring checklist card should list baseline tests, follow‑up frequency and symptoms that prompt urgent review.

Packaging visuals for blister and bottle packs and the 400 mg paediatric tablet are useful for patient leaflets and adherence aids.

Use plain language alt text, high‑contrast visuals and captions for accessibility and non‑specialist audiences.

Storage & Transport

How should patients and pharmacies look after mesalazine stock and prescriptions?

Store Asacol and other mesalazine tablets at 15–30°C and protect them from moisture and direct sunlight.

Keep products in their original blister pack or bottle to preserve labelling, expiry and batch details.

Rectal formulations may have specific storage instructions—always follow the leaflet.

When travelling, carry medication in hand luggage with a prescription or GP note to avoid questions at security and ensure supply continuity.

Return unused or expired medicines to a pharmacy for safe disposal and keep all products out of reach of children.

Guidelines For Proper Use

What practical steps should clinicians and patients follow for safe and effective treatment?

1. Confirm the indication of mild–moderate ulcerative colitis and consider rectal therapy for distal disease.
2. Perform baseline assessment including renal function, allergy history, pregnancy status and current medications.
3. Start induction dosing according to disease extent (2.4–4.8 g/day oral) and use Asacol 400 mg for children aged five and older where appropriate.
4. Review response at 6–8 weeks and step down to maintenance dosing of 1.6–2.4 g/day if remission is achieved.
5. Monitor creatinine at baseline and periodically during long‑term therapy, advise patients on side‑effect symptoms and missed‑dose instructions.
6. Discuss formulation preferences, dosing frequency and any planned brand switches due to possible release differences.

In our online pharmacy, salofalk is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Delivery Across United Kingdom

Final Notes For Clinicians And Patients

Mesalazine remains a cornerstone therapy for mild‑to‑moderate ulcerative colitis with robust evidence for induction and maintenance when doses and formulations are matched to disease extent.

Pharmacists should reinforce baseline and periodic renal monitoring and review interacting medicines such as NSAIDs and warfarin.

When switching brands be mindful of release characteristics, and discuss adherence strategies such as once‑daily options where clinically appropriate.

Patient education on storage, missed doses and prompt reporting of worrying symptoms improves safety and long‑term outcomes.

For specific product advice consult the relevant product leaflet and national guidelines when prescribing or dispensing mesalazine.